Effect of MIST on Esophageal Sensitivity in Patients With rGERD
NCT ID: NCT05429034
Last Updated: 2022-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
54 participants
INTERVENTIONAL
2022-06-30
2024-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of MIST on Esophageal Sensitivity in HV
NCT05427188
Effect of MIST on Esophageal Sensitivity: Pilot Study
NCT05760872
Physiology of GERD and Treatment Response
NCT04292470
Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula
NCT02425423
Important Correlation Between Anxiety and Reflux Symptoms in Patients With Gastroesophageal Reflux Disease
NCT06151067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
GERD patients can be divided into different categories based on upper endoscopy and pH or impedance-pH (MII-pH) monitoring. In the absence of lesions (esophagitis) during upper endoscopy, a pH or MII-pH monitoring will be performed. A first subcategory are patients with true GERD, characterized by an abnormal acid exposure and a positive or negative symptom association. The second and third category are patients with reflux hypersensitivity (RHS) and functional heartburn (FH)characterized by normal acid exposure on the MII-pH monitoring and a positive and negative symptom reflux association, respectively.
The basis for symptom generation/perception in GERD patients is not yet completely understood, but different mechanisms have been proposed including esophageal hypersensitivity, in which psychosocial stress is considered as a potential factor. This was shown in a study where 64% of the participants with heartburn reported that psychological factors, such as life stress, aggravate their symptoms. Furthermore, Fass et al. observed that auditory stress exacerbated symptom perception during esophageal acid perfusion. Moreover, our group investigated the effect of intravenous corticotrophin releasing hormone (CRH) on esophageal in healthy volunteers and showed that CRH is able to increase esophageal sensitivity to mechanical distention. Nevertheless, these previously performed studies in patients have some limitations: no measurable increase in cortisol (hypothalamo-pituitary-adrenal (HPA)-axis was not affected in these studies) and patients with RHS and FH - in whom the effect of stress is hypothesized to be the most relevant - were not included.
To induce moderate psychologic stress in the current study, the Montreal Imaging Stress Task (MIST) will be used. During this protocol, participants receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator (sham condition: threat components from the program and/or the investigator are absent). This MIST protocol can be used when investigating the effects of perceiving and processing psychosocial stress in the human brain in functional imaging studies.
Therefore, the investigators want to investigate the relation between sensitivity to different stimuli (esophageal sensitivity) and psychosocial stress in healthy volunteers and patients (True GERD, RHS and FH).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MIST-paradigm
Patients assigned to the MIST paradigm arm are exposed to psychosocial stress.
MIST paradigm
Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
Sham-paradigm
Patients assigned to the sham paradigm are not exposed to psychosocial stress.
Sham paradigm
Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MIST paradigm
Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
Sham paradigm
Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients need to be classified as having gastroesophageal reflux disease and can be divided in three different groups (based on the Lyon consensus):
* True GERD: Acid exposure time (AET) \>6% off PPI or \>80 reflux episodes on PPI
* RHS: AET \<4% off PPI or \<40 reflux episodes on PPI and positive symptom association
* FH: AET \<4% off PPI or \<40 reflux episodes on PPI and negative symptom association --\> Result based on a measurement maximum 1 year ago.
* Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.
* Being able to stop PPI intake for 10 - 14 days before the study visit.
Exclusion Criteria
* Systemic diseases, known to affect esophageal motility (i.e. systemic sclerosis);
* Surgery in the thorax or in the upper part of the abdomen (appendectomy and cholecystectomy are allowed);
* Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular, metabolic or gastrointestinal cerebrovascular disease as judged by the investigator;
* Severe anxiety/depressive disorder (assessed with the GAD7, PHQ9 and PHQ15);
* Medication intake that affect sensitivity: anti-depressants (selective serotonin re-uptake inhibitors and tricyclic antidepressants; SSRIs and TCA and daily use of benzodiazepines);
* Pregnancy or breastfeeding;
* History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Dr Jan Tack
PI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TARGID
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S65302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.